|
I do think it was because for the trial, they wanted patients who would more likely recur so they could measure a difference and 2cm (regardless of node status) is Stage 2 and not Stage 1 (where likelyhood of recurrence on its own) is more reduced. Especially since both the Hera and USA trials used chemotherapy as a mandatory requirement (thereby not testing the Herceptin alone).
Best regards,
Becky
|